Svenska
MENUMENU

PanSYM-1

PanSYM-1 is an ongoing prospective validation study for the early diagnosis of pancreatic cancer in patients with vague symptoms and other risk factors.

Testing for pancreatic cancer in patients with vague symptoms

The early symptoms of pancreatic cancer are often vague, making the disease difficult to detect. On average, it takes 6-9 months and 18 visits to the doctor before a patient with pancreatic cancer is actually diagnosed with cancer.

Testing for pancreatic cancer in risk groups with early, vague symptoms with IMMray™ PanCan-d could help clinicians to diagnose the cancer while it is still resectable by surgery, thereby dramatically improving survival rates, and at the same time lowering healthcare costs.

To this purpose, Immunovia is working actively on a global basis with Key Opinion Leaders (KOL) in an attempt to influence medical practice and national guidelines. The goal is to achieve routine testing of patients with vague symptom profiles were the clinician suspects – or wants to rule out – pancreatic cancer. In July 2017, one of the worlds most renowned experts in pancreatic cancer, professor Stephen Pereira at the University College London Hospital joined the advisory board.

PanSYM-1 a faster and more predictable study

PanSYM-1 was started with an interim study at the University College London Hospital in November 2017. 360 patient samples from risk groups with vague symptoms associated with early pancreatic cancer are being collected. Results are expected already in 2018. Immunovia will then proceed with a full-scale prospective validation study, provided the results of this interim study are encouraging.

Since some patients with early, vague symptoms will already have developed pancreatic cancer, the rate at which events (i.e. finding patients with cancer) are found will be higher. Because of this PanSYM-1 will likely be a faster and more predictable study than PanFAM-1. We estimate that PanSYM-1 will be completed at the same time as PanFAM-1, despite later initiation.

 

References:

  1. Suresh T. Chari et al. Summative Review: “Early Detection of Sporadic Pancreatic Cancer”, 2015
  2. Fiona M Walter et al.  Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study, Lancet Gastroenterol Hepatol 2016.
  3. ACE Cancer Decision Support Tools Cluster “Using Cancer Decision Support Tools to support the early diagnosis of cancer”, May 2017

Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports